Advances in the understanding and management of immune thrombocytopenia: a review of pathophysiology, risk factors, and treatment strategies
DOI:
https://doi.org/10.18203/2320-6012.ijrms20253214Keywords:
Immune thrombocytopenia, Immunopathogenesis, ITP Risk factors, Treatments, Recent advancementAbstract
An autoimmune disease known as immune thrombocytopenia (ITP) in which the immune system destroys platelets and the platelet count drops below 100,000/µl. The pathogenesis of ITP involves peripheral platelet destruction, impaired platelet production, and other mechanisms. Risk factors of ITP include environmental exposures, demographic factors, and genetic predispositions, all contributing to autoimmune responses. Diagnostic tests for ITP include complete blood count for low platelet counts, peripheral blood smear for platelet morphology, advanced autoantibody tests. Bone marrow examination for ruling out hematologic disorders, and spleen tissue analysis to understand platelet destruction and guide treatments. Treatment of ITP includes first-line therapies includes Corticosteroids, Intravenous immunoglobulin, anti-D immunoglobulin, second line therapies includes Rituximab, thrombopoietin receptor agonists, splenectomy and other therapies includes immuno-suppressants, and Fostamatinib. Some studies assessing response criteria in ITP patients. Recent advancement in ITP treatment involves spleen tyrosine kinase inhibitors, Bruton tyrosine kinase inhibitors, plasma cell-targeting agents, complement pathway, neuraminidase, and monoclonal antibodies. Also, in non-coding RNAs, CRISPR-associated protein 9 system, and Chimeric antigen receptor T-cell therapy. Recent research in ITP, animal models, includes in various species, mimic human ITP. This study concludes the understanding of ITP with various mechanisms and its advance therapies and treatment with ongoing latest research.
Metrics
References
Schoenaker JM, Nelson VS, Henderickx JGE, Terveer EM, Jansen AJG, Porcelijn L, et al. The intestinal flora: The key to unraveling heterogeneity in immune thrombocytopenia? Blood Rev. 2025;69:101252. DOI: https://doi.org/10.1016/j.blre.2024.101252
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86. DOI: https://doi.org/10.1182/blood-2009-06-225565
Grace RF, Long M, Kalish LA, Neufeld EJ. Applicability of 2009 International Consensus Terminology and Criteria for Immune Thrombocytopenia to a Clinical Pediatric Population. Pediatr Blood Cancer. 2012;58(2):216-20. DOI: https://doi.org/10.1002/pbc.23112
Rosu VE, Roșu ST, Ivanov AV, Starcea IM, Streanga V, Miron IC, et al. Predictor Factors for Chronicity in Immune Thrombocytopenic Purpura in Children. Children (Basel). 2023;10(6):911. DOI: https://doi.org/10.3390/children10060911
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93. DOI: https://doi.org/10.1182/blood-2008-07-162503
Litvinov RI, Weisel JW. Blood clot contraction: Mechanisms, pathophysiology, and disease. Res Pract Thromb Haemost. 2023;7(1):100023. DOI: https://doi.org/10.1016/j.rpth.2022.100023
Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-21. DOI: https://doi.org/10.1182/blood-2009-01-129155
Georgi JA, Middeke JM, Bornhäuser M, Matzdorff A, Trautmann-Grill K. Deciphering the genetic basis of immune thrombocytopenia: current evidence for genetic predisposition in adult ITP. Blood Adv. 2023;7(14):3710-24. DOI: https://doi.org/10.1182/bloodadvances.2023009949
Kuter DJ, Mayer J, Efraim M, Bogdanov LH, Baker R, Kaplan Z, et al. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia. Blood Adv. 2024;8(7):1715-24. DOI: https://doi.org/10.1182/bloodadvances.2023012044
Kalal S, Suresh K. Immune Thrombocytopenic Purpura - A Recurrent Case in a Young Lady. Acta Sci Womens Health. 2021;3(6):135-8. DOI: https://doi.org/10.31080/ASWH.2021.03.0241
Crickx E, Mahévas M, Michel M, Godeau B. Older Adults and Immune Thrombocytopenia: Considerations for the Clinician. Clin Interv Aging. 2023;18:115-30. DOI: https://doi.org/10.2147/CIA.S369574
Audia S, Mahévas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments. Hemasphere. 2021;5(6):e574. DOI: https://doi.org/10.1097/HS9.0000000000000574
Mititelu A, Onisâi MC, Roșca A, Vlădăreanu AM. Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options. Int J Mol Sci. 2024;25(4):2163. DOI: https://doi.org/10.3390/ijms25042163
Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620-32. DOI: https://doi.org/10.1016/j.autrev.2017.04.012
Lv Y, Shi H, Liu H, Zhou L. Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently? Front Immunol. 2022;13:953716. DOI: https://doi.org/10.3389/fimmu.2022.953716
Madkhali MA. Recent advances in the management of immune thrombocytopenic purpura (ITP): A comprehensive review. Medicine (Baltimore). 2024;103(3):e36936.
Kistanguri G, McCrae KR. Immune Thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495-520. DOI: https://doi.org/10.1016/j.hoc.2013.03.001
Martínez-Carballeira D, Bernardo Á, Caro A, Soto I, Gutiérrez L. Pathophysiology, Clinical Manifestations and Diagnosis of Immune Thrombocytopenia: Contextualization from a Historical Perspective. Hematol Rep. 2024;16(2):204-19. DOI: https://doi.org/10.3390/hematolrep16020021
Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022;76:103820. DOI: https://doi.org/10.1016/j.ebiom.2022.103820
González-López TJ, Newland A, Provan D. Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View. Medicina (Kaunas). 2023;59(4):815. DOI: https://doi.org/10.3390/medicina59040815
Matzdorff A, Alesci SR, Gebhart J, Holzhauer S, Hütter-Krönke ML, Kühne T, et al. Expert Report on Immune Thrombocytopenia: Current Diagnostics and Treatment – Recommendations from an Expert Group from Austria, Germany, and Switzerland. Oncol Res Treat. 2023;46(2):5-44. DOI: https://doi.org/10.1159/000529662
Hesham M, Hassan T, Fawzy A, Mohamed N, Alhejny E, Fathy M, et al. PTPN22 gene polymorphism as a genetic risk factor for primary immune thrombocytopenia in Egyptian children. Expert Rev Hematol. 2021;14(9):877-81. DOI: https://doi.org/10.1080/17474086.2020.1838895
Abdel Ghafar MT, Elshora OA, Allam AA, Mashaal RG, Hamous SAA, Abd El-Khalik SR, et al. Autoimmune Regulator Gene Polymorphisms and the Risk of Primary Immune Thrombocytopenic Purpura: A Case-Control Study. Int J Mol Sci. 2023;24(5):5007. DOI: https://doi.org/10.3390/ijms24055007
Pezeshki SMS, Saki N, Ghandali MV, Ekrami A, Avarvand AY. Effect of Helicobacter Pylori eradication on patients with ITP: a meta-analysis of studies conducted in the Middle East. Blood Res. 2021;56(1):38-43. DOI: https://doi.org/10.5045/br.2021.2020189
Kumar SM, Natarajan M, Vasudevan P, Prakash V, Kalyani VD. Prevalence of Helicobacter pylori infection in adult immune thrombocytopenia patients. Asian J Med Sci. 2023;14(10):128-32. DOI: https://doi.org/10.71152/ajms.v14i10.3413
Takeuchi H, Okamoto A. Helicobacter pylori Infection and Chronic Immune Thrombocytopenia. J Clin Med. 2022;11(16):4822. DOI: https://doi.org/10.3390/jcm11164822
Lv X, Li P, Yue P, Tang P, Zhou F. Risk factors and prognosis of thrombocytopenia in people living with HIV/AIDS. Ther Adv Hematol. 2023;14:20406207231170513. DOI: https://doi.org/10.1177/20406207231170513
Getawa S, Aynalem M, Bayleyegn B, Adane T. The global prevalence of thrombocytopenia among HIV-infected adults: A systematic review and meta-analysis. Int J Infect Dis. 2021;105:495-504. DOI: https://doi.org/10.1016/j.ijid.2021.02.118
Talargia F, Getacher L. Thrombocytopenia and Associated Factors Among HIV Infected Patients in Pre- and Post-Anti-Retroviral Therapy, North East Ethiopia. J Blood Med. 2021;12:741-8. DOI: https://doi.org/10.2147/JBM.S323086
Xu Y, Chen Y, Zhang L. Review: Advances in the Pathogenesis and Treatment of Immune Thrombocytopenia Associated with Viral Hepatitis. Glob Med Genet. 2023;10(3):229-33. DOI: https://doi.org/10.1055/s-0043-1772771
Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt VR. Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection. Mediterr J Hematol Infect Dis. 2017;9(1):e2017019. DOI: https://doi.org/10.4084/mjhid.2017.019
Páez-Guillán EM, Campos-Franco J, Alende R, Gonzalez-Quintela A. Hematological Abnormalities Beyond Lymphocytosis During Infectious Mononucleosis: Epstein-Barr Virus-Induced Thrombocytopenia. Mediterr J Hematol Infect Dis. 2023;15(1):e2023023. DOI: https://doi.org/10.4084/MJHID.2023.023
Cornudella Lema J, Sánchez-González B, Carrión-Barberà I, Vázquez Montes de Oca S, García Pallarols F, Salman-Monte TC. Immune thrombocytopenia in systemic lupus erythematosus: Prevalence, risk factors, and a novel predictive model for risk assessment. Med Clin (Barc). 2024;162(10):461-9. DOI: https://doi.org/10.1016/j.medcli.2023.12.012
Michel M. Adult Evans’ Syndrome. Hematol Oncol Clin North Am. 2022;36(2):381-92. DOI: https://doi.org/10.1016/j.hoc.2021.12.004
Fattizzo B, Carrai V, Crugnola M, Baldacci E, Bellini M, Bosi C, et al. Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey. Eur J Haematol. 2024;113(4):472-6. DOI: https://doi.org/10.1111/ejh.14256
Tomasello R, Giordano G, Romano F, Vaccarino F, Siragusa S, Lucchesi A, et al. Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary? Biomedicines. 2021;9(9):1170. DOI: https://doi.org/10.3390/biomedicines9091170
Mormile I, Punziano A, Riolo CA, Granata F, Williams M, de Paulis A, et al. Common Variable Immunodeficiency and Autoimmune Diseases: A Retrospective Study of 95 Adult Patients in a Single Tertiary Care Center. Front Immunol. 2021;12:652487. DOI: https://doi.org/10.3389/fimmu.2021.652487
Somasundaram N, Meyer O, Scheibenbogen C, Hanitsch LG, Stittrich A, Kölsch U, et al. Clinical and immunological characterisation of patients with common variable immunodeficiency related immune thrombocytopenia. Clin Exp Med. 2023;23(8):5423-32. DOI: https://doi.org/10.1007/s10238-023-01166-2
Zhou H, Yang J, Liu L, Zhang D, Zhou K, Li H, et al. The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population. Platelets. 2016;27(1):26-31. DOI: https://doi.org/10.3109/09537104.2015.1022142
Faki Osman ME. Childhood immune thrombocytopenia: Clinical presentation and management. Sudan J Paediatr. 2012;12(1):27-39.
Kim DS. Recent advances in treatments of adult immune thrombocytopenia. Blood Res. 2022;57(1):112-9. DOI: https://doi.org/10.5045/br.2022.2022038
Visweshwar N, Ayala I, Jaglal M, Killeen R, Sokol L, Laber DA, et al. Primary immune thrombocytopenia: a ‘diagnosis of exclusion’? Blood Coagul Fibrinolysis. 2022;33(6):289-94. DOI: https://doi.org/10.1097/MBC.0000000000001144
Kelton JG, Vrbensky JR, Arnold DM. How do we diagnose immune thrombocytopenia in 2018? Hematology Am Soc Hematol Educ Program. 2018;2018(1):561-7. DOI: https://doi.org/10.1182/asheducation-2018.1.561
Tomer A, Koziol J, Mcmillan R. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated autoantibodies against platelet-specific receptors. J Thromb Haemost. 2005;3(1):74-8. DOI: https://doi.org/10.1111/j.1538-7836.2004.01052.x
Beyene DA, Sisay EA, Fentie AM, Gebremedhin A. Treatment outcomes and adherence to treatment in patients with immune thrombocytopenia in two Ethiopian teaching hospitals: a retrospective cohort study. Sci Rep. 2024;14(1):11917. DOI: https://doi.org/10.1038/s41598-024-62372-w
Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99(7):1264-71. DOI: https://doi.org/10.3324/haematol.2013.103291
Semple JW. Animal models of immune thrombocytopenia (ITP). Ann Hematol. 2010;89(1):37-44. DOI: https://doi.org/10.1007/s00277-009-0882-8
Gil Gonzalez L, Won KD, Tawhidi Z, Cummins E, Cruz-Leal Y, Tundidor Cabado Y, et al. Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP. Blood Adv. 2024;8(8):1869-79. DOI: https://doi.org/10.1182/bloodadvances.2023012155
Neschadim A, Branch DR. Mouse Models for Immune-Mediated Platelet Destruction or Immune Thrombocytopenia (ITP). Curr Protoc Immunol. 2016;113(1):15. DOI: https://doi.org/10.1002/0471142735.im1530s113
Chow L, Aslam R, Speck ER, Kim M, Cridland N, Webster ML, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell–mediated responses that are differentially sensitive to therapy. Blood. 2010;115(6):1247-53. DOI: https://doi.org/10.1182/blood-2009-09-244772
Parmar RA, Patel KA. Immune Thrombocytopenic Purpura (ITP): A Comprehensive Review. GAIMS J Med Sci. 2024;4(1):103-7. DOI: https://doi.org/10.1097/MD.0000000000036936
Russo G, Parodi E, Farruggia P, Notarangelo LD, Perrotta S, Casale M, et al. Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology. Blood Transfus. 2024;22(3):253-65.
Khera S, Pramanik SK, Yanamandra U, Mishra K, Kapoor R, Das S. Dapsone: An Old but Effective Therapy in Pediatric Refractory Immune Thrombocytopenia. Indian J Hematol Blood Transfus. 2020;36(4):690-4. DOI: https://doi.org/10.1007/s12288-020-01286-9
Rast J, Schramm T, Mehic D, Fillitz M, Drexel T, Neusiedler-Nicolas V, et al. Management of Adult Patients with Newly Diagnosed or Relapsed Primary Immune Thrombocytopenia in Eastern Austria. Hämostaseologie: 2024; 5. DOI: https://doi.org/10.1055/a-2404-0306
Cheekati M, Murakhovskaya I. Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia. Biomedicines. 2024;12(7):1597. DOI: https://doi.org/10.3390/biomedicines12071597
Li W, Lv Y, Sun Y. Roles of non-coding RNA in megakaryocytopoiesis and thrombopoiesis: new target therapies in ITP. Platelets. 2023;34(1):2157382. DOI: https://doi.org/10.1080/09537104.2022.2157382
Qian BH, Ye X, Zhang L, Sun Y, Zhang JR, Gu ML, et al. Increased miR-155 Expression in Peripheral Blood Mononuclear Cells of Primary Immune Thrombocytopenia Patients Was Correlated with Serum Cytokine Profiles. Acta Haematol. 2014;133(3):257-63. DOI: https://doi.org/10.1159/000362150
Chang Y, Chen X, Tian Y, Gao X, Liu Z, Dong X, et al. Downregulation of microRNA-155-5p prevents immune thrombocytopenia by promoting macrophage M2 polarization via the SOCS1-dependent PD1/PDL1 pathway. Life Sci. 2020;257:118057. DOI: https://doi.org/10.1016/j.lfs.2020.118057
Li H, Hao Y, Zhang D, Fu R, Liu W, Zhang X, et al. Aberrant expression of long noncoding RNA TMEVPG1 in patients with primary immune thrombo -cytopenia. Autoimmunity. 2016;49(7):496-502. DOI: https://doi.org/10.3109/08916934.2016.1167192
Zhou J, Xu Y, Shu J, Jiang H, Huang L, Xu M, et al. GPIbα CAAR-T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia. Haematological. 2024;109(7):2256-70. DOI: https://doi.org/10.3324/haematol.2023.283874
Downloads
Published
How to Cite
Issue
Section
